Hikma releases generic Banzel

Hikma is introducing rufinamide tablets in dosage strengths of 200 mg and 400 mg.

The product is the generic of Novartis’ Banzel.

It is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients age 1-year-old and older and in adults.

Rufinamide tablets had a market value of roughly $285 million in the 12 months ended April 2021, according to IQVIA.

“We are proud to be among the first wave of generics to provide this important medicine,” said Brian Hoffmann, president of Hikma Generics. “Hikma also markets Rufinamide Oral Suspension, and we are pleased to add this new formulation to our portfolio. This launch demonstrates our ability to successfully deliver on our pipeline and launch new products, improving patients’ access to high-quality generic medicines.”